Literature DB >> 18393000

Current status of isolated limb infusion with mild hyperthermia for melanoma.

John F Thompson1, Peter C A Kam.   

Abstract

PURPOSE: Recurrent disease confined to a limb is a frequently encountered clinical problem in patients with melanoma. Regional chemotherapy by isolated limb perfusion (ILP) provides effective treatment but is invasive, complex and costly. Isolated limb infusion (ILI) is a simple yet effective alternative to ILP.
MATERIALS AND METHODS: ILI involves drug administration into a limb via percutaneously inserted catheters after vascular isolation of the limb has been achieved with a tourniquet. The infused drug is circulated for 30 minutes via a simple extracorporeal circuit incorporating a heater (to produce mild hyperthermia).
RESULTS: Limb tumour remission rates are similar to those achieved by conventional ILP. ILI is well tolerated, and elderly patients and those with major medical co-morbidities and serious peripheral vascular problems can be treated.
CONCLUSIONS: ILI with mild hyperthermia is an established alternative to hyperthermic ILP for patients with recurrent limb melanoma. It can also be used for patients with soft tissue sarcomas and a variety of serious, chronic dermatological conditions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393000     DOI: 10.1080/02656730701827565

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  2 in total

1.  Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms.

Authors:  Kiran K Turaga; Georgia M Beasley; John M Kane; Keith A Delman; Stephen R Grobmyer; Ricardo J Gonzalez; G Douglas Letson; David Cheong; Douglas S Tyler; Jonathan S Zager
Journal:  Arch Surg       Date:  2011-07

2.  Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases.

Authors:  Heiner Ruschulte; Serena Shi; William W Tseng; Kerstin Kolodzie; Philip C Crawford; Darren B Schneider; Mohammed Kashani-Sabet; David Minor; Christian Apfel; Stanley Pl Leong
Journal:  BMC Anesthesiol       Date:  2013-07-17       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.